Nirsevimab
INDICATIONS
FDA
FDA
- Prevention of lower respiratory tract disease from respiratory syncytial virus (RSV) in:
- Neonates and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease in their second RSV season
- RSV is the leading cause of hospitalization among infants in the U.S.[1]
- Most children are expected to be infected during their first year of life, and nearly all have been infected by the age of 2.
- The incidence of RSV hospitalization is three times higher in infants born at or before 30 weeks of gestation compared to infants born at term. Premature infants are also more likely to be admitted to the ICU for RSV disease compared to term infants.
- Most children (79%) under 24 months old hospitalized for RSV have no underlying medical conditions.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 14, 2024
Citation
Imburgia, Taylor. "Nirsevimab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540795/all/Nirsevimab.
Imburgia T. Nirsevimab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2024. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540795/all/Nirsevimab. Accessed December 7, 2024.
Imburgia, T. (2024). Nirsevimab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540795/all/Nirsevimab
Imburgia T. Nirsevimab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2024. [cited 2024 December 07]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540795/all/Nirsevimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nirsevimab
ID - 540795
A1 - Imburgia,Taylor,PharmD, BCPPS
Y1 - 2024/10/14/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540795/all/Nirsevimab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -